Shares of the shoe and apparel maker are reacting to reduced revenue guidance and word of government investigations into its accounting practices.
Black-market vaping has made the entire cannabis group toxic.
Several watchers and market players are deep in the weeds, tracking short action and key companies like Canopy Growth, trying to find out whether the industry has turned over a new leaf.
No company is safe from the litigation risk tied to the drug epidemic, but Johnson & Johnson may be one of the few guaranteed to survive.
Wall Street expects the healthcare giant can take the jolt from the penalty delivered by an Oklahoma judge in the state's opioid case against J&J.
With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.
Earnings misses, bad planning, and product-line execution problems are all hitting the retailer, but it's the macro woes that will also hurt its competitors.
After a 2018 high, marijuana stocks are gaining popularity again, but which ones are producing the most green for investors? Here are the charts.
What new management means for Mylan shareholders moving forward.
Pfizer will combine its off-patent drug business with Mylan in the as-yet-to-be-named new company.
A big jump in the market cap of Google's parent is in store thanks to an impressive second-quarter report.
Volatility reigns once again at the electric carmaker, which is seeing JB Straubel depart as chief technology officer.
Big-cap names have been driving the market, but some small-caps could make noise, too.
Watch closely as the government opens a broad antitrust investigation into unidentified leading online technology platforms
The loss of clients is a primary concern here.
It is unclear how a 'libra' denominated transaction might be governed in the future and it might require the creation of an entirely new oversight entity.
Surprise, surprise: Regulatory opposition toward digital currencies at home and abroad is rising against Facebook.
Deutsche is looking to drop the "bad bank" moniker with big moves on Monday.
Intra-Cellular Therapies and Acadia Pharmaceuticals are worth investors' attention.
The Federal Aviation Administration has declined to set a timeline on when it will lift its order prohibiting the troubled aircraft from flying.
The G-20 Summit in Japan could hold more intrigue than just the planned meeting between President Trump and Xi.
A number of vocal analysts and investors are calling for caution on those eager to buy the semiconductor stock amidst its Wednesday morning leap.
Micron is motivating more positive outlook on the semiconductor sector's road ahead.
Despite the financial positivity, many analysts warn the deal could have hiccups ahead.
PFE was ready to pay $160 billion until U.S. regulators blocked the deal.
The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.
A bit of context to simmer on following the big deal between Caesars and Eldorado.
Is prohibition the real factor propping up projections for demand and pricing in the cannabis market?
Oracle tells investors it can regain the crown it once held among enterprises and end-users, but some aren't so sure.
Is the bad news for Oracle all over?